{"transactions":[{"id":695223,"issuer":{"id":4898,"kind":"organization","name":"Obsidian Therapeutics, Inc."},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-05T20:10:43.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":37653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":37653,"derivative":{"exercise_price":12,"expiration_date":"2036-08-02","underlying":"Common Stock","underlying_shares":37653},"source":{"system":"sec-edgar","filing":"0001193125-26-335113","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733077/000119312526335113/ownership.xml","form_type":"4"}},{"id":739122,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:07:05.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733077/000119312526269397/ownership.xml","form_type":"4"}},{"id":1112813,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:37:36.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016972","document":"form4-06122025_080633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733077/000141588925016972/form4-06122025_080633.xml","form_type":"4"}},{"id":1476815,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-17T20:30:15.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.02,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-017207","document":"form4-06172024_040611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733077/000141588924017207/form4-06172024_040611.xml","form_type":"4"}},{"id":1784689,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-08T16:00:22.000Z","date":"2023-09-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the \"Merger Agreement\"), by and among the Issuer, Coherus BioSciences, Inc. (\"Coherus\"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus (\"Merger Sub I\"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the \"Effective Time\"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the \"First Merger\"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an \"In-the-Money Option\") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an \"In-the-Money Option\") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option."}],"balance_after":0,"derivative":{"exercise_price":0.69,"underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-23-048757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919123048757/doc4.xml","form_type":"4"}},{"id":1784688,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-09-08T16:00:22.000Z","date":"2023-09-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":83193,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the \"Merger Agreement\"), by and among the Issuer, Coherus BioSciences, Inc. (\"Coherus\"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus (\"Merger Sub I\"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the \"Effective Time\"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the \"First Merger\"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the \"Exchange Ratio\") shares of common stock of Coherus and (ii) one contingent value right (each, a \"CVR\") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-048757","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919123048757/doc4.xml","form_type":"4"}},{"id":1809949,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-11T20:00:09.000Z","date":"2023-08-01","kind":"sale","planned":false,"acquired":false,"shares":16713,"price":0.94,"value":15710.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Amount reported represents the number of shares sold by the reporting person to cover the tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":83193,"source":{"system":"sec-edgar","filing":"0001209191-23-045494","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919123045494/doc4.xml","form_type":"4"}},{"id":1856825,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-13T20:30:43.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":13200,"derivative":{"exercise_price":2.8,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0001415889-23-009741","document":"form4-06132023_040623.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733077/000141588923009741/form4-06132023_040623.xml","form_type":"4"}},{"id":1973912,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T20:00:29.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest in full on February 8, 2024, so long as the reporting person remains an employee or other service provider of the Issuer on such date."}],"balance_after":400000,"derivative":{"exercise_price":0.69,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-23-016052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919123016052/doc4.xml","form_type":"4"}},{"id":2193325,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-08-05T20:00:46.000Z","date":"2022-08-03","kind":"sale","acquired":false,"shares":10594,"price":1.72,"value":18221.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Amount reported represents the number of shares sold by the reporting person to cover the tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":99906,"source":{"system":"sec-edgar","filing":"0001209191-22-044673","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919122044673/doc4.xml","form_type":"4"}},{"id":2226484,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:08:24.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on June 15, 2022 and will vest in three equal installments on June 15, 2023, June 15, 2024 and June 15, 2025."}],"balance_after":26400,"derivative":{"exercise_price":2.28,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001415889-22-006704","document":"form4-06172022_010602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733077/000141588922006704/form4-06172022_010602.xml","form_type":"4"}},{"id":2354799,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T20:00:42.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":359000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in equal monthly installments over four years, so that all of the underlying shares shall be vested on February 8, 2026, so long as the reporting person remains an employee or other service provider of the Issuer on such dates."}],"balance_after":359000,"derivative":{"exercise_price":3.64,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":359000},"source":{"system":"sec-edgar","filing":"0001209191-22-015966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919122015966/doc4.xml","form_type":"4"}},{"id":2354798,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-03T20:00:42.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest as follows:  40% on August 1, 2022 and the remaining 60% on August 1, 2023, so long as the reporting person remains an employee or other service provider of the Issuer on such date."}],"balance_after":110500,"source":{"system":"sec-edgar","filing":"0001209191-22-015966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919122015966/doc4.xml","form_type":"4"}},{"id":2434952,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-14T20:30:27.000Z","date":"2021-07-21","kind":"sale","acquired":false,"shares":33500,"price":6.1,"value":204350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Amount reported represents the number of shares sold by the reporting person to cover the tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":54500,"source":{"system":"sec-edgar","filing":"0001209191-22-003397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919122003397/doc4.xml","form_type":"4"}},{"id":2794791,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-11T20:00:17.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":484280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Amendment to the Form 4 filed by the reporting person on March 3, 2021 is filed to correct the vesting schedule previously reported in Table II. This option shall become exercisable in equal monthly installments over four years following April 1, 2021, so long as the reporting person remains an employee or other service provider of the Company on such dates."}],"balance_after":484280,"derivative":{"exercise_price":11.24,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":484280},"source":{"system":"sec-edgar","filing":"0001209191-21-019971","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919121019971/doc4a.xml","form_type":"4/A","original_submission_date":"2021-03-03"}},{"id":2814118,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-03T20:18:58.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":484280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall become exercisable in equal monthly installments over four years following February 9, 2021, so long as the reporting person\nremains an employee or other service provider of the Company on such dates."}],"balance_after":484280,"derivative":{"exercise_price":11.24,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":484280},"source":{"system":"sec-edgar","filing":"0001209191-21-017481","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919121017481/doc4.xml","form_type":"4"}},{"id":2850457,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-18T20:00:19.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":1000,"price":11.35,"value":11350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020."}],"balance_after":88000,"source":{"system":"sec-edgar","filing":"0001209191-21-012182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919121012182/doc4.xml","form_type":"4"}},{"id":2906123,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-15T20:00:12.000Z","date":"2021-01-15","kind":"sale","acquired":false,"shares":2000,"price":12.25,"value":24500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020."}],"balance_after":89000,"source":{"system":"sec-edgar","filing":"0001209191-21-003916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919121003916/doc4.xml","form_type":"4"}},{"id":2906122,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-15T20:00:12.000Z","date":"2021-01-14","kind":"sale","acquired":false,"shares":7000,"price":11.95,"value":83650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020."}],"balance_after":91000,"source":{"system":"sec-edgar","filing":"0001209191-21-003916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919121003916/doc4.xml","form_type":"4"}},{"id":2940326,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-17T20:00:09.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":1000,"price":10.48,"value":10480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020."}],"balance_after":98000,"source":{"system":"sec-edgar","filing":"0001209191-20-064253","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919120064253/doc4.xml","form_type":"4"}},{"id":2944579,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-15T20:00:09.000Z","date":"2020-12-11","kind":"sale","acquired":false,"shares":1405,"price":10.05,"value":14120.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020."}],"balance_after":99000,"source":{"system":"sec-edgar","filing":"0001209191-20-063630","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919120063630/doc4.xml","form_type":"4"}},{"id":2981476,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-13T20:00:10.000Z","date":"2020-11-11","kind":"sale","acquired":false,"shares":595,"price":10.05,"value":5979.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020."}],"balance_after":100405,"source":{"system":"sec-edgar","filing":"0001209191-20-058406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919120058406/doc4.xml","form_type":"4"}},{"id":3005360,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-10-16T20:02:46.000Z","date":"2020-10-14","kind":"sale","acquired":false,"shares":4000,"price":10.05,"value":40200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020."}],"balance_after":101000,"source":{"system":"sec-edgar","filing":"0001209191-20-055191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919120055191/doc4.xml","form_type":"4"}},{"id":3288912,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-05T16:05:18.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall become exercisable in equal monthly installments over four years following January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such dates."}],"balance_after":80000,"derivative":{"exercise_price":3.18,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-20-006846","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919120006846/doc4.xml","form_type":"4"}},{"id":3288911,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-05T16:05:18.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in full on the date 18 months after January 21, 2020, so long as the reporting person remains an employee or\nother service provider of the Company on such date."}],"balance_after":105000,"source":{"system":"sec-edgar","filing":"0001209191-20-006846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919120006846/doc4.xml","form_type":"4"}},{"id":3619448,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-04T18:05:32.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments after February 12, 2019."}],"balance_after":90000,"derivative":{"exercise_price":4.27,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-19-015872","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919119015872/doc4.xml","form_type":"4"}},{"id":3700465,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-08T16:05:36.000Z","date":"2019-01-04","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested and became exercisable with respect to the first 25% of the option grant on November 7, 2017, and the remainder vests and becomes exercisable in 36 equal monthly installments thereafter until November 7, 2020."}],"balance_after":256578,"derivative":{"exercise_price":4.136,"expiration_date":"2026-12-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-19-000741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000089924319000741/doc4.xml","form_type":"4"}},{"id":3700464,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":26133,"kind":"person","name":"ROSS ROBERT W.","position":1,"cik":"0001733077","reported_name":"ROSS ROBERT W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-01-08T16:05:36.000Z","date":"2019-01-04","kind":"exercise","acquired":true,"shares":25000,"price":4.136,"value":103400.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0000899243-19-000741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000089924319000741/doc4.xml","form_type":"4"}}]}